ReviewRadiologie (Heidelberg, Germany)2026
[Sarcomas : Clinical introduction].
Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcomas are malignant tumors of connective and supporting tissues characterized by substantial biological and clinical heterogeneity. Their optimal treatment requires specialized expertise, particularly in radiological diagnostics. The correct interpretation of imaging procedures represents the first crucial step in treatment planning. Radiologists play a key role by recognizing suspicious findings and initiating early referral to specialized sarcoma centers. Depending on the histological subtype, sarcomas require tailored imaging strategies. A notable example is whole-body magnetic resonance imaging (MRI) for the detection of osseous metastases in myxoid liposarcoma. The assessment of treatment response in the neoadjuvant setting also poses a particular challenge as it is not uncommon for treatment-related imaging changes to mimic tumor progression (pseudoprogression) and must be reliably distinguished from true progression. During follow-up an appropriate balance between oncologic safety, such as early detection of local recurrence or metastases, and minimizing cumulative radiation exposure must be achieved.
Indexed as
Identifiers
41729231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.